On Thursday, Evernorth Health Services said its Accredo arm will make a Humira biosimilar available to patients with no out-of-pocket costs. Evernorth is a subsidiary of The Cigna Group (NYSE:CI). Beginning in June, the high- and low-concentration interchangeable biosimilar will be produced for Evernorth’s affiliate private-label pharmaceutical distributor, Quallent Pharmaceuticals, through agreements with multiple manufacturers. Most patients will be able to secure the biosimilar products for $0 out-of-pocket through the copay assistance programs offered at Quallent beginning in June, Evernorth said. This program is estimated to save individual ...